Insider Trading Activity Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) – Insider Sold 1,445 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)

John F. Neylan , Insider of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) reportedly Sold 1,445 shares of the company’s stock at an average price of 7.14 for a total transaction amount of $10,317.30 SEC Form

Insider Trading History For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)

On 10/3/2012 James F Oliviero III, CFO, sold 4,973 with an average share price of $2.72 per share and the total transaction amounting to $13,526.56.View SEC Filing

On 5/13/2013 James F Oliviero III, CFO, sold 29,363 with an average share price of $8.34 per share and the total transaction amounting to $244,887.42.View SEC Filing

On 7/5/2013 Ron Bentsur, CEO, sold 2,440 with an average share price of $7.95 per share and the total transaction amounting to $19,398.00.View SEC Filing

On 7/5/2013 James F Oliviero III, CFO, sold 1,438 with an average share price of $7.95 per share and the total transaction amounting to $11,432.10.View SEC Filing

On 10/3/2013 Ron Bentsur, CEO, sold 2,505 with an average share price of $10.25 per share and the total transaction amounting to $25,676.25.View SEC Filing

On 10/3/2013 James Oliviero III, CFO, sold 1,475 with an average share price of $10.25 per share and the total transaction amounting to $15,118.75.View SEC Filing

On 12/30/2013 James Oliviero III, CFO, sold 109,500 with an average share price of $12.64 per share and the total transaction amounting to $1,384,080.00.View SEC Filing

Analyst Ratings For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
These are 6 Hold Ratings, 4 Buy Ratings .
The current consensus rating for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is Hold (Score: 2.40) with a consensus target price of $8.33 , a potential (18.54% upside)

Analyst Ratings History For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)

On 8/7/2015 MLV & Co. Reiterated Rating Buy with a price target of $25.00
On 8/10/2015 Roth Capital Downgraded rating Buy to Neutral with a price target of $11.00 to $6.00
On 2/26/2016 J P Morgan Chase & Co Downgraded rating Overweight to Neutral
On 3/29/2016 BTIG Research Reiterated Rating Sell with a price target of $2.50
On 8/2/2016 Stifel Nicolaus Downgraded rating Buy to Hold
On 8/2/2016 Brean Capital Downgraded rating Buy to Hold
On 8/2/2016 Ladenburg Thalmann Financial Services Boost Price Target of rating Buy with a price target of $9.00 to $10.00

Recent Trading Activity for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
Shares of Keryx Biopharmaceuticals, Inc. closed the previous trading session at 7.03 up +0.02 0.29% with 1,100,346 shares trading hands.